• Omer, A. B., Altayb, H. N., Al-Abbasi, F. A., Gupta, G., Ahmed, M. M., Alghamdi, A. M., ... & Kazmi, I. (2023). Acemannan ameliorates STZ-activated diabetes by attenuating high glucose via inhibiting inflammatory cytokines and apoptosis pathway. International Journal of Biological Macromolecules, 253, 127127.
• Saifi, M. A., Shaikh, A. S., Kaki, V. R., & Godugu, C. (2022). Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes. Journal of Cellular Physiology, 237(5), 2516-2527.
• Schaller, G., Kolodjaschna, J., Pleiner, J., Mittermayer, F., Kapiotis, S., Schmetterer, L., & Wolzt, M. (2008). Pioglitazone does not affect vascular or inflammatory responses after endotoxemia in humans. Hormone and metabolic research, 40(08), 549-555.
• Luksch, A., Rainer, G., Koyuncu, D., Ehrlich, P., Maca, T., Gschwandtner, M. E., ... & Schmetterer, L. (2005). Effect of nimodipine on ocular blood flow and colour contrast sensitivity in patients with normal tension glaucoma. British journal of ophthalmology, 89(1), 21-25.
• Ahmad, A. O., Mohanty, P. K., & Yadav, P. K. (2024). Review on Epcoritamab: A New FDA-Approved Medicine for Adult Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma. International Journal of Research in Pharmacy and Allied Science, 3(1), 91-103.